Kisqali

Ribociclib, the active ingredient in Kisqali, is a CDK4/6 inhibitor presented as an unknown strength/unknown form for oral use. It treats hormone receptor‑positive, HER2‑negative advanced or metastatic breast cancer in adults. GNH USA supplies Kisqali as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Kisqali is a CDK4/6 inhibitor used in the management of hormone‑driven breast cancer pathways. - Hormone receptor‑positive, HER2‑negative advanced breast cancer: combined with an aromatase inhibitor to delay disease progression. - Hormone receptor‑positive, HER2‑negative metastatic breast cancer: combined with fulvestrant to improve progression‑free survival. - Post‑menopausal women with HR+ HER2‑negative breast cancer: used with endocrine therapy to extend treatment benefit.

Common Side Effects: - Neutropenia: reduced white blood cell count. - Nausea: feeling of sickness. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Alopecia: hair thinning or loss. - Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils. - Hepatotoxicity: liver enzyme elevations or injury. - QT interval prolongation: potential cardiac rhythm disturbance. - Interstitial lung disease: inflammation of lung tissue. - Severe infections: opportunistic or bacterial infections. - Pulmonary embolism: blood clot in lung arteries.

Before initiating therapy, patients should be evaluated for baseline blood counts, liver function, and cardiac status. - Monitor blood counts: check CBC regularly for neutropenia. - Assess liver function: test hepatic enzymes before and during treatment. - Evaluate QT interval: perform ECG if risk factors for prolongation exist. - Avoid strong CYP3A4 inhibitors: drugs like ketoconazole can increase ribociclib exposure. - Use effective contraception: ribociclib may cause fetal harm. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Ribociclib may interact with several concomitant medications. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase ribociclib levels. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): reduce ribociclib efficacy. - QT‑prolonging agents (e.g., sotalol, amiodarone): heighten risk of cardiac arrhythmia. Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect absorption. - CYP2C8 substrates (e.g., paclitaxel): possible altered metabolism. - Warfarin: monitor INR for potential anticoagulation changes.